Protein Mislocalization: Mechanisms, Functions and Clinical Applications in Cancer

Overview

Journal Biochim Biophys Acta

Specialties Biochemistry
Biophysics

Date 2014 Apr 9

PMID 24709009

Citations 48

Authors

Xiaohong Wang

Shulin Li

Affiliations

Soon will be listed here.

Abstract

The changes from normal cells to cancer cells are primarily regulated by genome instability, which foster hallmark functions of cancer through multiple mechanisms including protein mislocalization. Mislocalization of these proteins, including oncoproteins, tumor suppressors, and other cancer-related proteins, can interfere with normal cellular function and cooperatively drive tumor development and metastasis. This review describes the cancer-related effects of protein subcellular mislocalization, the related mislocalization mechanisms, and the potential application of this knowledge to cancer diagnosis, prognosis, and therapy.

Citing Articles

Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy-A Narrative Review.

Kedzierska M, Bankosz M J Clin Med. 2024; 13(23).

PMID: 39685591 PMC: 11642550. DOI: 10.3390/jcm13237131.

Procollagen-lysine 2-oxoglutarate 5-dioxygenases are responsible for 5R-hydroxylysine modification of therapeutic T-cell bispecific monoclonal antibodies produced by Chinese hamster ovary cells.

Bauer N, Boettger M, Papadaki S, Leitner T, Klostermann S, Kettenberger H Front Bioeng Biotechnol. 2024; 12:1414408.

PMID: 39530057 PMC: 11551027. DOI: 10.3389/fbioe.2024.1414408.

Targeted protein relocalization via protein transport coupling.

Ng C, Liu A, Cui B, Banik S Nature. 2024; 633(8031):941-951.

PMID: 39294374 PMC: 11761438. DOI: 10.1038/s41586-024-07950-8.

Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia.

Zhang Z, Huang J, Zhang Z, Shen H, Tang X, Wu D Biomark Res. 2024; 12(1):60.

PMID: 38858750 PMC: 11165883. DOI: 10.1186/s40364-024-00600-1.

Analysis of the nischarin expression across human tumor types reveals its context-dependent role and a potential as a target for drug repurposing in oncology.

Ostojic M, duric A, Zivic K, Grahovac J PLoS One. 2024; 19(5):e0299685.

PMID: 38781180 PMC: 11115306. DOI: 10.1371/journal.pone.0299685.

References

Li C, Fang F, Wang J, Tzeng C, Tai H, Wei Y . EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact. Ann Surg Oncol. 2011; 19(2):443-54. DOI: 10.1245/s10434-011-1942-6. View

Wilson C, Ramos L, Villasenor M, Anders K, Press M, Clarke K . Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999; 21(2):236-40. DOI: 10.1038/6029. View

Dittmann K, Mayer C, Rodemann H . Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol. 2010; 186(1):1-6. DOI: 10.1007/s00066-009-2026-4. View

Runnebaum I, Kieback D, Mobus V, Tong X, Kreienberg R . Subcellular localization of accumulated p53 in ovarian cancer cells. Gynecol Oncol. 1996; 61(2):266-71. DOI: 10.1006/gyno.1996.0137. View

Yang X, Wang J, Liu C, Grizzle W, Yu S, Zhang S . Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts. Am J Pathol. 2005; 167(3):705-19. PMC: 1698724. DOI: 10.1016/S0002-9440(10)62045-7. View

Rubinfeld B, Robbins P, Albert I, Porfiri E, Polakis P . Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 1997; 275(5307):1790-2. DOI: 10.1126/science.275.5307.1790. View

Li Y, Yu W, Ren J, Chen W, Huang L, Kharbanda S . Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003; 1(10):765-75. View

Nouman G, Anderson J, Lunec J, Angus B . The role of the tumour suppressor p33 ING1b in human neoplasia. J Clin Pathol. 2003; 56(7):491-6. PMC: 1769994. DOI: 10.1136/jcp.56.7.491. View

Lilling G, Nordenberg J, Rotter V, Goldfinger N, Peller S, Sidi Y . Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. Cancer Invest. 2002; 20(4):509-17. DOI: 10.1081/cnv-120002151. View

10.

Li C, Iida M, Dunn E, Ghia A, Wheeler D . Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009; 28(43):3801-13. PMC: 2900381. DOI: 10.1038/onc.2009.234. View

11.

Mandic R, Schamberger C, Muller J, Geyer M, Zhu L, Carey T . Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res. 2005; 11(19 Pt 1):6845-52. DOI: 10.1158/1078-0432.CCR-05-0378. View

12.

Bitler B, Goverdhan A, Schroeder J . MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 2010; 123(Pt 10):1716-23. PMC: 2864713. DOI: 10.1242/jcs.062661. View

13.

Petkovic S, MUTAVDZIC M . The late results of conservative surgery for ureteral tumours. Br J Urol. 1968; 40(4):412-4. DOI: 10.1111/j.1464-410x.1968.tb11823.x. View

14.

Wang Y, Yamaguchi H, Hsu J, Hung M . Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene. 2010; 29(28):3997-4006. PMC: 2904849. DOI: 10.1038/onc.2010.157. View

15.

Siragusa M, Zerilli M, Iovino F, Francipane M, Lombardo Y, Ricci-Vitiani L . MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res. 2007; 67(11):5522-30. DOI: 10.1158/0008-5472.CAN-06-4197. View

16.

Shubbar E, Kovacs A, Hajizadeh S, Parris T, Nemes S, Gunnarsdottir K . Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer. 2013; 13:1. PMC: 3545739. DOI: 10.1186/1471-2407-13-1. View

17.

Nagaraj N, Singh O, Merchant N . Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy. Expert Rev Proteomics. 2010; 7(4):613-23. PMC: 4339030. DOI: 10.1586/epr.10.70. View

18.

Kojima K, Konopleva M, Samudio I, Shikami M, Cabreira-Hansen M, McQueen T . MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005; 106(9):3150-9. PMC: 1895324. DOI: 10.1182/blood-2005-02-0553. View

19.

Rakha E, Boyce R, Abd El-Rehim D, Kurien T, Green A, Paish E . Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005; 18(10):1295-304. DOI: 10.1038/modpathol.3800445. View

20.

Joshi M, Ahmad R, Yin L, Raina D, Rajabi H, Bubley G . MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther. 2009; 8(11):3056-65. PMC: 2783220. DOI: 10.1158/1535-7163.MCT-09-0646. View